These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1428207)

  • 1. Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients.
    Kinugasa E; Akizawa T; Nakashima Y; Wakasa M; Koshikawa S
    Int J Artif Organs; 1992 Oct; 15(10):595-600. PubMed ID: 1428207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
    Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
    Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
    Akizawa T
    Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs.
    Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T
    Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
    Yang JW; Han BG; Kim BR; Lee YH; Kim YS; Yu JM; Choi SO
    Ren Fail; 2009; 31(8):668-75. PubMed ID: 19814633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin.
    Lim JY; Kim JB; Choo SJ; Chung CH; Lee JW; Jung SH
    Ann Thorac Surg; 2016 Aug; 102(2):534-9. PubMed ID: 27083248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
    Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
    Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke.
    Sakamoto T; Kano H; Miyahara S; Inoue T; Izawa N; Gotake Y; Matsumori M; Okada K; Okita Y
    J Heart Valve Dis; 2014 Nov; 23(6):744-51. PubMed ID: 25790622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
    Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
    Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
    Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
    Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation with nafamostat mesilate during extracorporeal life support.
    Lang Y; Zheng Y; Qi B; Zheng W; Wei J; Zhao C; Gao W; Li T
    Int J Cardiol; 2022 Nov; 366():71-79. PubMed ID: 35850387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
    Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
    Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
    Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
    Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
    Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
    Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
    Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
    Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
    Baek NN; Jang HR; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    Ren Fail; 2012; 34(3):279-85. PubMed ID: 22251267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate.
    Hu ZJ; Iwama H; Suzuki R; Kobayashi S; Akutsu I
    Intensive Care Med; 1999 May; 25(5):524-7. PubMed ID: 10401950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
    Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
    J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.